Johannes van der Loo, PhD

Director, Aseptic Processing Laboratories

Director, Vector Production Facility

Director, Research Viral Vector Core

Field Service Associate Professor, UC Department of Pediatrics

Phone 513-803-1066

Fax 513-636-1446

Email Han.vanderloo@cchmc.org

Development, scale-up and clinical production of viral vectors and cellular products

Dr. van der Loo has been employed by Cincinnati Children's since 2002 where he is the Director of the Aseptic Processing Laboratories, an ISO Class 7 and 8 cleanroom facility for the manufacture of GMP-grade viral vectors and manipulation of GMP/GTP-grade cellular products for phase I/II Clinical Trials in compliance US federal and European guidelines. In addition, he is the director of the Vector Production Facility, the director of the Research Viral Vector Core and the chair of the Cincinnati Children's Institutional Biosafety Committee (IBC). His previous appointment as assistant professor (1998-2002) was with the Department of Hematology/Oncology and Transplantation, at the University of Minnesota School of Medicine, in Minneapolis, MN. 

Dr. van der Loo is the director of the Cincinnati Children's Hospital Medical Center's Aseptic Processing Laboratories, Vector Production Facility and Research Viral Vector Core.

BS: Biology, State University of Utrecht, the Netherlands, 1983.

MS: Medical Biology, State University of Utrecht, the Netherlands, 1987.

Teaching degree: Biology, State University of Utrecht, Netherlands, 1989.

PhD: Hematology, Erasmus University Rotterdam, the Netherlands, 1995.

Postdoctoral Fellowship: Hematology, Howard Hughes Medical Institute, Indiana University, Indianapolis, IN, 1994-1998.

van der Loo JC, Swaney WP, Grassman E, Terwilliger A, Higashimoto T, Schambach A, Baum C, Thrasher AJ, Williams DA et al. Scale-up and manufacturing of clinical-grade self-inactivating gamma-retroviral vectors by transient transfection. Gene Ther. 2012;19(3):246-254.

van der Loo JC, Swaney WP, Grassman E, Terwilliger A, Higashimoto T, Schambach A, Baum C, Thrasher AJ, Cavazzana-Calvo M, Hacein-Bey-Abina S, Williams DA, Nordling DL, Reeves L, Malik P. Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency. Gene Ther. 2012;19(8):872-876.

Schambach A, Swaney WP, van der Loo JC. Design and production of retro- and lentiviral vectors for gene expression in hematopoietic cells. Methods Mol Biol. 2009;506:191-205.

Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, Zimmerman SL, Smolarek T, Dishop MK, Wert SE, Whitsett JA, Grabowski G, Carey BC, Stevens C, van der Loo JC, Trapnell BC. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med. 2008 Nov 24;205(12):2703-10.

Carey B, Staudt MK, Bonaminio D, van der Loo JC, Trapnell BC. PU.1 redirects adenovirus to lysosomes in alveolar macrophages, uncoupling internalization from infection. J Immunol. 2007 Feb 15;178(4):2440-7.

Novel Scalable Vector Production Systems Development Core. Principle Investigator. CCTST PCS T1 Pilot Collaborative Studies Grant funded by Institutional Clinical and Translational Science Award, NIH/NCRR. Jul 2013 - Jun 2015. 8UL1TR000077-04.